Pacific Biosciences Of California (PACB) Capital Expenditures (QoQ) (2010 - 2026)
Pacific Biosciences Of California (PACB) Capital Expenditures (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Pacific Biosciences Of California | 428.15 Mn | 152.18 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 253.43% |
| Dec 31, 2025 | 1,101.16% |
| Sep 30, 2025 | -115.64% |
| Jun 30, 2025 | -60.40% |
| Mar 31, 2025 | -14.10% |
| Dec 31, 2024 | 305.46% |
| Sep 30, 2024 | -153.21% |
| Jun 30, 2024 | -61.87% |
| Mar 31, 2024 | 91.65% |
| Dec 31, 2023 | 143.86% |
| Sep 30, 2023 | -63.40% |
| Jun 30, 2023 | -39.05% |
| Mar 31, 2023 | -24.12% |
| Dec 31, 2022 | 17.07% |
| Sep 30, 2022 | 4.23% |
| Jun 30, 2022 | 10.47% |
| Mar 31, 2022 | 28.01% |
| Jun 30, 2021 | 291.27% |
| Mar 31, 2021 | 498.51% |
| Dec 31, 2020 | -87.50% |